Aldevron Breakthrough Blog
Personalized Gene Editing Treatments
May 19, 2025 by Aldevron
A look at the backstory
With the news of the manufacture of the world’s first mRNA-based personalized CRISPR therapy shared at the 28th ASGCT Annual Meeting, how that success came about has been the subject of many discussions.
Several articles from the New England Journal of Medicine provide a substantial background of how this major accomplishment was achieved. Learn more about the steps in the development process with these NEJM articles:
- Editorial: Progress in the Development of N-of-1 Therapy
- Editorial: Science Behind the Study: Personalized Gene Editing to Treat an Inborn Error of Metabolism
- Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
For more information about the manufacturing process for the treatment, visit the Aldevron website’s News section.
- Have questions on this topic? Contact Us
- Learn more about our mRNA services
- Visit our Gene Editing / CRISPR web page
Aldevron serves the biotechnology industry with custom production of nucleic acids and proteins. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from research grade to clinical trials to commercial applications. Aldevron specializes in cGMP manufacturing and is known for inventing the GMP-Source® quality system. Aldevron operates the largest cGMP plasmid DNA manufacturing facility in the world at company headquarters in Fargo, North Dakota, with additional facilities in Madison, Wisconsin.